American Financial Group Inc. Holds Position in Axovant Sciences Ltd. (AXON)
American Financial Group Inc. held its stake in shares of Axovant Sciences Ltd. (NYSE:AXON) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 172,395 shares of the biotechnology company’s stock at the end of the second quarter. American Financial Group Inc. owned 0.16% of Axovant Sciences worth $3,998,000 as of its most recent SEC filing.
Several other hedge funds also recently modified their holdings of AXON. Oppenheimer & Co. Inc. bought a new stake in shares of Axovant Sciences during the first quarter worth $219,000. Norges Bank acquired a new stake in Axovant Sciences during the fourth quarter worth approximately $508,000. AQR Capital Management LLC acquired a new stake in Axovant Sciences during the fourth quarter worth approximately $139,000. Primecap Management Co. CA raised its stake in Axovant Sciences by 300.1% in the first quarter. Primecap Management Co. CA now owns 2,878,930 shares of the biotechnology company’s stock worth $43,011,000 after buying an additional 2,159,428 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its stake in Axovant Sciences by 1,718.3% in the first quarter. Point72 Asset Management L.P. now owns 209,100 shares of the biotechnology company’s stock worth $3,124,000 after buying an additional 197,600 shares in the last quarter. 94.54% of the stock is owned by institutional investors and hedge funds.
Shares of Axovant Sciences Ltd. (AXON) opened at 21.01 on Monday. Axovant Sciences Ltd. has a 52-week low of $11.01 and a 52-week high of $26.49. The company’s market capitalization is $2.26 billion. The company has a 50-day moving average of $22.68 and a 200 day moving average of $19.46.
Axovant Sciences (NYSE:AXON) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by $0.12. Analysts predict that Axovant Sciences Ltd. will post ($2.41) earnings per share for the current year.
A number of analysts have commented on the stock. BidaskClub lowered shares of Axovant Sciences from a “hold” rating to a “sell” rating in a report on Saturday. Jefferies Group LLC reaffirmed a “buy” rating and set a $31.00 target price on shares of Axovant Sciences in a report on Friday, June 9th. Oppenheimer Holdings, Inc. lifted their target price on shares of Axovant Sciences from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday, June 14th. Cowen and Company reaffirmed an “outperform” rating and set a $30.00 target price (up previously from $22.00) on shares of Axovant Sciences in a report on Tuesday, June 13th. Finally, CIBC lifted their target price on shares of Axovant Sciences from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday, June 14th. Three investment analysts have rated the stock with a sell rating and nine have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $27.75.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axovant Sciences Ltd. (NYSE:AXON).
Receive News & Stock Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related stocks with our FREE daily email newsletter.